• Je něco špatně v tomto záznamu ?

B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma

B. Dai, M. Grau, M. Juilland, P. Klener, E. Höring, J. Molinsky, G. Schimmack, SM. Aukema, E. Hoster, N. Vogt, AM. Staiger, T. Erdmann, W. Xu, K. Erdmann, N. Dzyuba, H. Madle, WE. Berdel, M. Trneny, M. Dreyling, K. Jöhrens, P. Lenz, A. Rosenwald,...

. 2017 ; 129 (3) : 333-346. [pub] 20161118

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc18016907

Grantová podpora
NV15-27757A MZ0 CEP - Centrální evidence projektů

Mantle cell lymphoma (MCL) is a mature B-cell lymphoma characterized by poor clinical outcome. Recent studies revealed the importance of B-cell receptor (BCR) signaling in maintaining MCL survival. However, it remains unclear which role MALT1, an essential component of the CARD11-BCL10-MALT1 complex that links BCR signaling to the NF-κB pathway, plays in the biology of MCL. Here we show that a subset of MCLs is addicted to MALT1, as its inhibition by either RNA or pharmacologic interference induced cytotoxicity both in vitro and in vivo. Gene expression profiling following MALT1 inhibition demonstrated that MALT1 controls an MYC-driven gene expression network predominantly through increasing MYC protein stability. Thus, our analyses identify a previously unappreciated regulatory mechanism of MYC expression. Investigating primary mouse splenocytes, we could demonstrate that MALT1-induced MYC regulation is not restricted to MCL, but represents a common mechanism. MYC itself is pivotal for MCL survival because its downregulation and pharmacologic inhibition induced cytotoxicity in all MCL models. Collectively, these results provide a strong mechanistic rationale to investigate the therapeutic efficacy of targeting the MALT1-MYC axis in MCL patients.

Cluster of Excellence EXC 1003 Cells in Motion Münster Germany Department of Medicine A Hematology Oncology and Pneumology University Hospital Münster Münster Germany

Department of Biochemistry University of Lausanne Epalinges Switzerland

Department of Clinical Pathology Robert Bosch Hospital Stuttgart Germany

Department of Hematology and Oncology Robert Bosch Hospital Stuttgart Germany Dr Margarete Fischer Bosch Institute of Clinical Pharmacology and University of Tuebingen Tuebingen Germany

Department of Hematology Charles University General Hospital Prague Prague Czech Republic

Department of Internal Medicine 3 Ludwig Maximilians University Hospital Munich Munich Germany

Department of Internal Medicine 3 Ludwig Maximilians University Hospital Munich Munich Germany Institute of Medical Informatics Biometry and Epidemiology Ludwig Maximilians University of Munich Munich Germany

Department of Pathology University of Würzburg Würzburg Germany

Department of Physics Philipps University Marburg Germany

Dr Margarete Fischer Bosch Institute of Clinical Pharmacology and University of Tuebingen Tuebingen Germany Department of Clinical Pathology Robert Bosch Hospital Stuttgart Germany

Hematopathology Section and Lymph Node Registry Department of Pathology University Hospital Schleswig Holstein Campus Kiel Kiel Germany

Institute of Human Genetics Christian Albrechts University Kiel Kiel Germany

Institute of Human Genetics Christian Albrechts University Kiel Kiel Germany Institute of Human Genetics University Hospital Ulm Ulm Germany

Institute of Pathological Physiology 1st Faculty of Medicine Charles University Prague Prague Czech Republic Department of Hematology Charles University General Hospital Prague Prague Czech Republic

Institute of Pathology Charité Universitätsmedizin Berlin Berlin Germany

Institute of Pathology University Hospital Basel Switzerland

Research Unit Cellular Signal Integration Institute of Molecular Toxicology and Pharmacology Helmholtz Zentrum München German Research Center for Environmental Health Neuherberg Germany

Translational Oncology Albert Schweitzer Campus 1 University Hospital Münster Münster Germany Cluster of Excellence EXC 1003 Cells in Motion Münster Germany

Translational Oncology Albert Schweitzer Campus 1 University Hospital Münster Münster Germany Cluster of Excellence EXC 1003 Cells in Motion Münster Germany Department of Medicine A Hematology Oncology and Pneumology University Hospital Münster Münster Germany

Translational Oncology Albert Schweitzer Campus 1 University Hospital Münster Münster Germany Cluster of Excellence EXC 1003 Cells in Motion Münster Germany Fachbereich Chemie und Pharmazie University of Münster Münster Germany

Translational Oncology Albert Schweitzer Campus 1 University Hospital Münster Münster Germany Hematopathology Section and Lymph Node Registry Department of Pathology University Hospital Schleswig Holstein Campus Kiel Kiel Germany

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18016907
003      
CZ-PrNML
005      
20201019150509.0
007      
ta
008      
180515s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/blood-2016-05-718775 $2 doi
035    __
$a (PubMed)27864294
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Dai, Beiying $u Translational Oncology, Albert-Schweitzer-Campus 1, University Hospital Münster, Münster, Germany. Cluster of Excellence EXC 1003, Cells in Motion, Münster, Germany. Fachbereich Chemie und Pharmazie, University of Münster, Münster, Germany.
245    10
$a B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma / $c B. Dai, M. Grau, M. Juilland, P. Klener, E. Höring, J. Molinsky, G. Schimmack, SM. Aukema, E. Hoster, N. Vogt, AM. Staiger, T. Erdmann, W. Xu, K. Erdmann, N. Dzyuba, H. Madle, WE. Berdel, M. Trneny, M. Dreyling, K. Jöhrens, P. Lenz, A. Rosenwald, R. Siebert, A. Tzankov, W. Klapper, I. Anagnostopoulos, D. Krappmann, G. Ott, M. Thome, G. Lenz,
520    9_
$a Mantle cell lymphoma (MCL) is a mature B-cell lymphoma characterized by poor clinical outcome. Recent studies revealed the importance of B-cell receptor (BCR) signaling in maintaining MCL survival. However, it remains unclear which role MALT1, an essential component of the CARD11-BCL10-MALT1 complex that links BCR signaling to the NF-κB pathway, plays in the biology of MCL. Here we show that a subset of MCLs is addicted to MALT1, as its inhibition by either RNA or pharmacologic interference induced cytotoxicity both in vitro and in vivo. Gene expression profiling following MALT1 inhibition demonstrated that MALT1 controls an MYC-driven gene expression network predominantly through increasing MYC protein stability. Thus, our analyses identify a previously unappreciated regulatory mechanism of MYC expression. Investigating primary mouse splenocytes, we could demonstrate that MALT1-induced MYC regulation is not restricted to MCL, but represents a common mechanism. MYC itself is pivotal for MCL survival because its downregulation and pharmacologic inhibition induced cytotoxicity in all MCL models. Collectively, these results provide a strong mechanistic rationale to investigate the therapeutic efficacy of targeting the MALT1-MYC axis in MCL patients.
650    _2
$a zvířata $7 D000818
650    _2
$a kaspasy $x metabolismus $x fyziologie $7 D020169
650    _2
$a buněčná smrt $7 D016923
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a viabilita buněk $7 D002470
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a heterografty $7 D064593
650    _2
$a lidé $7 D006801
650    _2
$a lymfom z plášťových buněk $x metabolismus $7 D020522
650    _2
$a myši $7 D051379
650    _2
$a protein MALT1 $7 D000074884
650    _2
$a NF-kappa B $x metabolismus $7 D016328
650    _2
$a nádorové proteiny $x metabolismus $x fyziologie $7 D009363
650    _2
$a protoonkogenní proteiny c-myc $x metabolismus $7 D016271
650    _2
$a receptory antigenů B-buněk $x fyziologie $7 D011947
650    _2
$a signální transdukce $7 D015398
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Grau, Michael $u Translational Oncology, Albert-Schweitzer-Campus 1, University Hospital Münster, Münster, Germany. Cluster of Excellence EXC 1003, Cells in Motion, Münster, Germany.
700    1_
$a Juilland, Mélanie $u Department of Biochemistry, University of Lausanne, Epalinges, Switzerland.
700    1_
$a Klener, Pavel $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University Prague, Prague, Czech Republic. Department of Hematology, Charles University General Hospital Prague, Prague, Czech Republic.
700    1_
$a Höring, Elisabeth $u Department of Hematology and Oncology, Robert Bosch Hospital, Stuttgart, Germany. Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology and University of Tuebingen, Tuebingen, Germany.
700    1_
$a Molinsky, Jan $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University Prague, Prague, Czech Republic. Department of Hematology, Charles University General Hospital Prague, Prague, Czech Republic.
700    1_
$a Schimmack, Gisela $u Research Unit Cellular Signal Integration, Institute of Molecular Toxicology and Pharmacology, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany.
700    1_
$a Aukema, Sietse M $u Institute of Human Genetics, Christian-Albrechts University Kiel, Kiel, Germany.
700    1_
$a Hoster, Eva $u Department of Internal Medicine III, Ludwig-Maximilians University Hospital Munich, Munich, Germany. Institute of Medical Informatics, Biometry, and Epidemiology, Ludwig-Maximilians University of Munich, Munich, Germany.
700    1_
$a Vogt, Niklas $u Translational Oncology, Albert-Schweitzer-Campus 1, University Hospital Münster, Münster, Germany. Hematopathology Section and Lymph Node Registry, Department of Pathology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
700    1_
$a Staiger, Annette M $u Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology and University of Tuebingen, Tuebingen, Germany. Department of Clinical Pathology, Robert Bosch Hospital, Stuttgart, Germany.
700    1_
$a Erdmann, Tabea $u Translational Oncology, Albert-Schweitzer-Campus 1, University Hospital Münster, Münster, Germany. Cluster of Excellence EXC 1003, Cells in Motion, Münster, Germany.
700    1_
$a Xu, Wendan $u Translational Oncology, Albert-Schweitzer-Campus 1, University Hospital Münster, Münster, Germany. Cluster of Excellence EXC 1003, Cells in Motion, Münster, Germany.
700    1_
$a Erdmann, Kristian $u Translational Oncology, Albert-Schweitzer-Campus 1, University Hospital Münster, Münster, Germany. Cluster of Excellence EXC 1003, Cells in Motion, Münster, Germany.
700    1_
$a Dzyuba, Nicole $u Translational Oncology, Albert-Schweitzer-Campus 1, University Hospital Münster, Münster, Germany. Cluster of Excellence EXC 1003, Cells in Motion, Münster, Germany.
700    1_
$a Madle, Hannelore $u Translational Oncology, Albert-Schweitzer-Campus 1, University Hospital Münster, Münster, Germany. Cluster of Excellence EXC 1003, Cells in Motion, Münster, Germany.
700    1_
$a Berdel, Wolfgang E $u Cluster of Excellence EXC 1003, Cells in Motion, Münster, Germany. Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany.
700    1_
$a Trneny, Marek $u Department of Hematology, Charles University General Hospital Prague, Prague, Czech Republic.
700    1_
$a Dreyling, Martin $u Department of Internal Medicine III, Ludwig-Maximilians University Hospital Munich, Munich, Germany.
700    1_
$a Jöhrens, Korinna $u Institute of Pathology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
700    1_
$a Lenz, Peter $u Department of Physics, Philipps University, Marburg, Germany.
700    1_
$a Rosenwald, Andreas $u Department of Pathology, University of Würzburg, Würzburg, Germany.
700    1_
$a Siebert, Reiner $u Institute of Human Genetics, Christian-Albrechts University Kiel, Kiel, Germany. Institute of Human Genetics, University Hospital Ulm, Ulm, Germany; and.
700    1_
$a Tzankov, Alexandar $u Institute of Pathology, University Hospital, Basel, Switzerland.
700    1_
$a Klapper, Wolfram $u Hematopathology Section and Lymph Node Registry, Department of Pathology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
700    1_
$a Anagnostopoulos, Ioannis $u Institute of Pathology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
700    1_
$a Krappmann, Daniel $u Research Unit Cellular Signal Integration, Institute of Molecular Toxicology and Pharmacology, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany.
700    1_
$a Ott, German $u Department of Clinical Pathology, Robert Bosch Hospital, Stuttgart, Germany.
700    1_
$a Thome, Margot $u Department of Biochemistry, University of Lausanne, Epalinges, Switzerland.
700    1_
$a Lenz, Georg $u Translational Oncology, Albert-Schweitzer-Campus 1, University Hospital Münster, Münster, Germany. Cluster of Excellence EXC 1003, Cells in Motion, Münster, Germany. Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany.
773    0_
$w MED00000807 $t Blood $x 1528-0020 $g Roč. 129, č. 3 (2017), s. 333-346
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27864294 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20201019150509 $b ABA008
999    __
$a ok $b bmc $g 1300531 $s 1013747
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 129 $c 3 $d 333-346 $e 20161118 $i 1528-0020 $m Blood $n Blood $x MED00000807
GRA    __
$a NV15-27757A $p MZ0
LZP    __
$a Pubmed-20180515

Najít záznam

Citační ukazatele

Možnosti archivace